Theravance director receives shares and options grant

Q: What did Theravance Biopharma (TBPH) director Dean J. Mitchell receive in this Form 4?

Dean J. Mitchell received 6,009 ordinary shares and a grant of options for 13,398 ordinary shares as equity compensation, according to the Form 4 insider transaction data.

Q: What is the exercise price of the new Theravance Biopharma (TBPH) options?

The newly granted options have an exercise price of $16.64 per share. This is the price at which Dean J. Mitchell can buy Theravance Biopharma ordinary shares under the option grant.

Q: How many Theravance Biopharma (TBPH) shares does Dean J. Mitchell hold after this grant?

After the grant, Dean J. Mitchell directly holds 97,213 ordinary shares of Theravance Biopharma. This total reflects his position following the 6,009-share award reported in the Form 4.

Q: How do the new Theravance Biopharma (TBPH) options vest for Dean J. Mitchell?

The options vest as to 1/12 of the shares each month of continuous service following the grant date, with any remaining unvested options vesting on the date of the next annual shareholder meeting if he remains in service.

Q: When do the newly granted Theravance Biopharma (TBPH) options expire?

The granted options expire on June 11, 2036. After that date, Dean J. Mitchell will no longer be able to exercise these options to acquire ordinary shares at the stated exercise price.

Theravance Biopharma director Dean J. Mitchell received equity compensation, gaining 6,009 ordinary shares and a grant of options for 13,398 ordinary shares.

Accepted by SEC EDGAR 06/16/2026 - 09:37 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Theravance Biopharma director Dean J. Mitchell received equity compensation, gaining 6,009 ordinary shares and a grant of options for 13,398 ordinary shares. The options have an exercise price of $16.64 per share and vest monthly, with remaining unvested options vesting by the next annual shareholder meeting if service continues.

Insider Trade Summary

Grant/Award: 19,407 shares

Grant/Award 2 txns

Insider MITCHELL DEAN J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	13,398	$0.00	$0.00
Grant/Award	Ordinary Shares	6,009	$0.00	$0.00

Holdings After Transaction: Share Option (Right to Buy) — 13,398 contracts (Direct); Ordinary Shares — 97,213 shares (Direct)

Holdings Before and After: Share Option (Right to Buy), 0 to 13,398 contracts (Direct); Ordinary Shares, 91,204 to 97,213 shares (Direct)

Footnotes (1)

F1. This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.

Key Figures

Share grant: 6,009 ordinary shares Options granted: 13,398 options Exercise price: $16.64 per share +3 more

6 metrics

Share grant 6,009 ordinary shares Equity award to Dean J. Mitchell

Options granted 13,398 options Share Option (Right to Buy) grant

Exercise price $16.64 per share Strike price of granted options

Shares after grant 97,213 ordinary shares Total direct holdings after transaction

Option expiration June 11, 2036 End of exercise period for options

Vesting schedule 1/12 monthly Portion of option shares vest each month of service

Key Terms

Share Option (Right to Buy), exercise price, continuous month of service, annual meeting of the company's shareholders

4 terms

exercise price financial

"conversion_or_exercise_price: "16.6400""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

continuous month of service other

"when optionee completes each continuous month of service following the grant date"

annual meeting of the company's shareholders other

"shall vest on the date of the next annual meeting of the company's shareholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Theravance Biopharma (TBPH) director Dean J. Mitchell receive in this Form 4?

Dean J. Mitchell received 6,009 ordinary shares and a grant of options for 13,398 ordinary shares as equity compensation, according to the Form 4 insider transaction data.

What is the exercise price of the new Theravance Biopharma (TBPH) options?

The newly granted options have an exercise price of $16.64 per share. This is the price at which Dean J. Mitchell can buy Theravance Biopharma ordinary shares under the option grant.

How many Theravance Biopharma (TBPH) shares does Dean J. Mitchell hold after this grant?

After the grant, Dean J. Mitchell directly holds 97,213 ordinary shares of Theravance Biopharma. This total reflects his position following the 6,009-share award reported in the Form 4.

How do the new Theravance Biopharma (TBPH) options vest for Dean J. Mitchell?

The options vest as to 1/12 of the shares each month of continuous service following the grant date, with any remaining unvested options vesting on the date of the next annual shareholder meeting if he remains in service.

When do the newly granted Theravance Biopharma (TBPH) options expire?

The granted options expire on June 11, 2036. After that date, Dean J. Mitchell will no longer be able to exercise these options to acquire ordinary shares at the stated exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MITCHELL DEAN J

(Last)

(First)

(Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	06/12/2026		A		6,009	A	$0	97,213	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Share Option (Right to Buy)	$16.64	06/12/2026		A		13,398		⁽¹⁾	06/11/2036	Ordinary Shares	13,398	$0	13,398	D

Explanation of Responses:

1. This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.

	/s/ Brett A. Grimaud, Attorney-in-Fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR